Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer (Q44653206)

5 December 2017

Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer (English)

1 reference

5 December 2017

0 references

1 reference

5

1 reference

5 December 2017

Michael J Zelefsky

8

0 references

Yoshiya Yamada

2

object named as

Yoshiya Yamada

1 reference

5 December 2017

6

Marisa Kollmeier

1 reference

5 December 2017

Zumre A Alicikus

1

1 reference

5 December 2017

Zhigang Zhang

3

1 reference

5 December 2017

Xin Pei

4

1 reference

5 December 2017

Brett Cox

7

1 reference

5 December 2017

language of work or name

English

0 references

publication date

8 November 2010

1 reference

5 December 2017

1 reference

5 December 2017

117

1 reference

5 December 2017

7

1 reference

5 December 2017

1429-1437

1 reference

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

5 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Inverse planning algorithms for external beam radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

The potential and limitations of the inverse radiotherapy technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Radiation dose and late failures in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Role of IMRT in reducing penile doses in dose escalation for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

Prostate cancer radiotherapy dose response: an update of the fox chase experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

Ultra-High Dose (86.4 Gy) IMRT for Localized Prostate Cancer: Toxicity and Biochemical Outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

The effect of treatment positioning on normal tissue dose in patients with prostate cancer treated with three-dimensional conformal radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25467

7 January 2021

Identifiers

DOI

10.1002/CNCR.25467

1 reference

release_wcgzbu6oqrckreajdj4bguvchy

5 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wcgzbu6oqrckreajdj4bguvchy

24 November 2022

mapped directly with Wikidata item

1 reference